AI Solid Form Engineering
AI-Driven Solid Form Engineering
Stability Optimization & Manufacturability Enhancement for Clinical-Stage Assets
Unexpected polymorph behavior is not just a theoretical risk — it is a manufacturability variable.
In clinical-stage small molecules, narrow thermodynamic separation between structurally distinct forms can reduce crystallization robustness and increase process sensitivity during scale-up or tech transfer.
We help teams quantify stability margin and engineer more controllable solid-form strategies before critical CMC milestones.
Why This Matters in Development
Polymorph confirmation at lab scale does not guarantee process robustness. When alternative forms exist within a narrow stability window (<1 kcal/mol), competitive behavior may emerge under:
- Solvent variation
- Scale-dependent crystallization kinetics
- Slurry aging
- Tech transfer
- Process stress
This can result in:
- Unexpected form conversion
- Batch variability
- Additional crystallization optimization
- Extended analytical investigation
- CMC clarification cycles
Solid-form robustness is a development variable — not just a discovery observation.
What We Deliver
Our program goes beyond risk identification. We provide structured engineering insight:
- Crystal structure prediction landscape mapping
- Quantitative thermodynamic stability margin analysis
- Energy–density competition mapping
- Packing motif differentiation
- Competitive polymorph window definition
- Engineering guidance to enhance robustness
- Executive-level summary for decision support
Designed for milestone-aligned decision-making.
When Teams Engage Us
- Preparing for Phase I or Phase II scale-up
- Strengthening CMC package prior to BD discussions
- Evaluating robustness before tech transfer
- Investigating unexpected solid-form behavior
- Exploring alternative forms to enhance manufacturability
Discuss Your Program
If your team is advancing a small-molecule asset toward clinical expansion or manufacturing scale-up, we would be glad to review your development context.
Schedule a 20-minute discussion.
Contact: wayne.wang@agilgen.com | www.agilgen.com
Hours — Open today 09:00 am – 05:00 pm
Get in Touch
If your team is advancing a small-molecule asset toward clinical expansion or manufacturing scale-up, we would be glad to review your development context. Schedule a 20-minute discussion.